Overview |
bs-4053R-FITC |
MAVS Polyclonal Antibody, FITC Conjugated |
WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
Mouse |
Human, Rat, Cow |
Specifications |
FITC |
Rabbit |
KLH conjugated synthetic peptide derived from human MAVS |
3-100/540 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
5788 |
Cytoplasm |
CARD adapter inducing interferon beta; Card; Interferon beta promoter stimulator protein 1; Interferon-beta promoter stimulator protein 1; Ips 1; Ips1; KIAA1271; Mitochondrial anti viral signaling protein; Mitochondrial Antiviral Signaling; Mitochondrial antiviral signaling protein; Putative NF kappa B activating protein 031N; Virus induced signaling adapter; DKFZp547C224; DKFZp666M015; FLJ27482; FLJ31698; FLJ35386; FLJ38051; CARD; FLJ41962; IPS-1; IPS1; MGC3260; VISA; MAVS_HUMAN. |
MAVS (Mitochondrial Antiviral Signaling) mediates the activation of NF-kappaB and IRF3 in response to antiviral infection. Silencing of MAVS expression permits derepression of viral replication, while over expression of MAVS boosts antiviral immunity. |
Application Dilution |
WB |
1:300-5000 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |